This combination exhibited strong antitumor effects, suggesting that the TR2.4-1BB receptor can augment CAR-T cell responses against both MUC1 and HER2 antigens, effectively eliminating MDSCs and leading to improved T-cell survival, proliferation, and persistence at the tumor site [236]. Here, ERBB2 is linked to neoplasm.